2022 World Conference on Lung Cancer (ePosters)-EP08.01-057. Pembrolizumab Maintenance in Patients with Metastatic Squamous Non-Small Cell Lung Cancer (sNSCLC)

EP08.01-057. Pembrolizumab Maintenance in Patients with Metastatic Squamous Non-Small Cell Lung Cancer (sNSCLC) - AIO-TRK-0115/PRIMUS

Back to course

Pdf Summary

The PRIMUS trial evaluated the efficacy and safety of pembrolizumab maintenance treatment in patients with metastatic squamous non-small cell lung cancer (sNSCLC). The trial aimed to explore the potential of pembrolizumab in enhancing the efficacy of systemic treatment in this patient population.<br /><br />In this phase II trial, patients with stage IV squamous NSCLC who had stable disease after at least two cycles of first-line cis- or carboplatin-based chemotherapy were randomized to receive pembrolizumab maintenance treatment or placebo. Planned enrollment was not fully met due to changes in clinical treatment standards, resulting in 16 patients receiving pembrolizumab and 18 patients receiving placebo.<br /><br />The primary endpoint of the trial was progression-free survival (PFS), and secondary endpoints included objective response rate (ORR), overall survival (OS), and safety. The results showed a notable benefit of pembrolizumab maintenance treatment compared to placebo in terms of both PFS and OS.<br /><br />Median PFS was 9.5 months with pembrolizumab compared to 4.8 months with placebo, and median OS was 24.0 months with pembrolizumab compared to 10.9 months with placebo. The objective response rate was similar between the treatment arms, but the rate of stable disease was higher with pembrolizumab.<br /><br />The incidence of adverse events was balanced between the treatment arms, with no unexpected safety concerns identified.<br /><br />In conclusion, pembrolizumab maintenance treatment showed a significant benefit in terms of PFS and OS in patients with metastatic squamous NSCLC. These findings support the use of pembrolizumab as a potential effective and well-tolerated treatment option for these patients. Further exploration is warranted to validate these results.

Asset Subtitle

Martin Reck

Meta Tag

Speaker Martin Reck

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

PRIMUS trial

pembrolizumab

maintenance treatment

metastatic squamous non-small cell lung cancer

sNSCLC

efficacy

safety

progression-free survival

overall survival

adverse events